Principal Investigator
Bradley Gampel
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20241359
Clinical Trial Summary
Phase 2 Study of Olutasidenib with Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor IDH1 Mutations
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Neurological Cancer
Contact Information
Phone Number
305-243-2647